3 stocks that can turn $1,000 into $5,000 by 2030

Finding the highest growth prospects for a market at any given point in time is not that difficult. But finding stocks that could increase fivefold in value over the next five years is a different story. Their underlying companies must do everything right and operate in industries that can continue to generate serious growth. Even temporary declines in these stocks help. Certainly that is a tall order.

But there are a few such names available right now. Here’s a closer look at three of the best stocks that have the potential to turn your $1,000 investment into a $5,000 position by the end of 2030.

Amazon

Amazon (AMZN 2.39%) Of course, it is also a leader in e-commerce in the Western Hemisphere. It controls 40% of the North American market, according to figures from Digital Commerce 360. The results aren’t too shabby overseas either. The international segment experienced 12% top-line growth in the third quarter of last year, and looks set to move deeper into the black and eventually remain there. (The North American e-commerce division has been in the black for some time, but operating profit is also increasing above average.)

None of these are reasons you might want to consider stepping into shares of Amazon, hoping for a heroic five-year turnaround in the stock.

Rather, the key to the bullish argument here is the company’s cloud computing business. It is known as Amazon Web Services or AWS. AWS now accounts for more than 60% of the company’s operating profit, thanks to revenue growth of 19% last quarter and similar growth rates year-to-date. That number is still growing very quickly.

Data source: Amazon Inc. Charts by author. The numbers are in billions.

This is important because the cloud computing market still has a lot of growth ahead of it. Mordor Intelligence predicts that the global cloud computing market will grow at a CAGR of more than 16% through 2030.

The continued expansion of Amazon’s e-commerce operations doesn’t detract from its optimistic argument. Investors seem to be underestimating all this.

Iovance Biotherapeutics

I’ve had a tough time over the past four years. Iovance Biotherapeutics (IOVA 2.60%) shareholder. The stock gained a lot of popularity between 2019 and 2020, finally peaking at $54.21 in January 2021 before plummeting to a 2023 low of $3.21. The current price of close to $6.00 is not great.

But these sharp sell-offs can sometimes be fantastic buying opportunities rooted in investors’ collective belief that their timing is bad.

But first things first.

As the name suggests, Iovance Biotherapeutics is a biopharmaceutical name. Its flagship product is Lipileucel, a tumor-infiltrating lymphocyte (TIL) treatment that has been in the works for several years, but first received FDA approval (for the treatment of melanoma) in February 2024. This was widely expected, but still failed. This is an important milestone for the company in generating pre-commercial revenue.

The response was good. Iovance sold about $60 million worth of the young (and expensive) drug in the three months through September 2024.

However, investors did not remain optimistic about this success.

What do we offer?

The action here is somewhat typical of small-cap biopharma stocks working on single, truly game-changing drug candidates. The company burned all its bullishness based on future euphoria in 2019 and 2020 when it first became clear that Refilucell was likely to receive approval. In the three years between then and its approval, investors largely lost interest.

The irony is that Iovance Biotherapeutics’ growth story has never been more compelling. Credence Research predicts that the tumor-infiltrating lymphocyte drug market, still nascent and underserved, is poised to grow approximately 40% annually through 2032, reaching approximately $2.5 billion. Given that Iovance is one of the first and few companies successfully researching this science, investors should price in potential and actual growth in the near future.

year

Add it last. year (year 0.97%) Add to the list of stocks that could turn $1,000 into $5,000 by 2030.

Like Iovance, Roku stock soared early in the COVID-19 pandemic (and even because of it). Millions of people were suddenly stuck at home with little to do except watch television. Roku’s streaming player makes this possible.

As could be expected after this stock’s unchecked meteoric rise, the market eventually began to recognize that its then-high valuation meant little. The stock lost more than 80% of its value during 2021 and 2022, and has remained stagnant ever since. The company’s lack of profitability during this period certainly didn’t help either.

Now take a closer look… well, what Roku is and what it does. Despite giving up some of that share recently, Roku still controls a whopping 37% of the North American connected TV (CTV) device market, according to industry research firm Pixalate. The next closest competitor in this crowded field is still far behind at 17%.

Although the company is not doing well overseas, this is because the company is focusing more time and resources on its domestic market, where it is doing very well and where most of the opportunities lie. According to Global Markets Insights, the global streaming/video-on-demand market is expected to grow at a CAGR of 11% through 2032, led by North America, where more than 40% of this business takes place.

But that’s not the only bullish catalyst poised to push this stock higher.

Roku briefly swung into the black in pandemic-hit 2021 and then slipped back into the red, but its current revenue and income trajectory could see it back in the black by next year. It is unlikely to be of great benefit. Analysts are only looking for earnings per share of $0.36 in 2026. However, this is not the end of this growing trend. Its top and bottom lines should continue to improve beyond that.

Data source: StockAnalytics. Chart by author.

In anticipation of what is becoming increasingly clear, it is likely that stocks will begin to rally long before this feat of viability is achieved.